Behaviour in children with neurofibromatosis type 1: Cognition, executive function, attention, emotion, and social competence

Developmental Medicine and Child Neurology

Volumn 55, Issue 2, 2013, Pages 111-125

  Lehtonen, Annukka ^a   Howie, Emma ^b   Trump, Dorothy ^a   Huson, Susan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ATTENTION; BEHAVIOR DISORDER; BIBLIOGRAPHIC DATABASE; BRAIN FUNCTION; CANCER PATIENT; CHILD; CHILD BEHAVIOR; CHILD CARE; CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; COMPREHENSION; DATA SYNTHESIS; DEPTH PERCEPTION; EMBASE; EMOTION; EMOTIONAL DISORDER; EXECUTIVE FUNCTION; FACIAL EXPRESSION; HUMAN; INTELLIGENCE; INTELLIGENCE TEST; LANGUAGE; LANGUAGE ABILITY; MEDLINE; MEMORY; MEMORY DISORDER; MOTOR PERFORMANCE; NEUROFIBROMATOSIS; PEER REVIEW; PHENOTYPE; PRIORITY JOURNAL; PSYCINFO; REVIEW; SKILL; SOCIAL BEHAVIOR; SOCIAL COMPETENCE; SPEECH; SYSTEMATIC REVIEW; TASK PERFORMANCE; THINKING; TUMOR LOCALIZATION; VERBAL MEMORY;

ATTENTION; CHILD; CHILD BEHAVIOR; COGNITION; EMOTIONS; EXECUTIVE FUNCTION; HUMANS; NEUROFIBROMATOSIS 1; NEUROPSYCHOLOGICAL TESTS; SOCIAL ADJUSTMENT;

EID: 84872595392     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2012.04399.x     Document Type: Review

References (96)

1. Evans DG, Howard E, Giblin C, et al.Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A: 327-32.
2. Ferner RE, Huson SM, Thomas N, et al.Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44: 81-8.
3. Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005; 65: 1037-44.
4. Johnson H, Wiggs L, Stores G, Huson SM. Psychological disturbance and sleep disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2005; 47: 237-42.
5. Lezak M, Howieson D, Loring D. Neuropsychological Assessment, 4th edn. New York: Oxford University Press, 2004.
6. Kayl AE, Moore BD 3rd. Behavioural phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 2000; 6: 117-24.
7. Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE. Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol 2006; 13: 8-20.
8. North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol 2002; 17: 605-12; discussion 627-9, 646-51.
9. Ozonoff S. Cognitive impairment in neurofibromatosis type 1. Am J Med Genet 1999; 89: 45-52.
10. Hachon C, Iannuzzi S, Chaix Y. Behavioural and cognitive phenotypes in children with neurofibromatosis type 1 (NF1): the link with the neurobiological level. Brain Dev 2011; 33: 52-61.
11. Payne JM, Moharir MD, Webster R, North KN. Brain structure and function in neurofibromatosis type 1: current concepts and future directions. J Neurol Neurosurg Psychiatry 2010; 81: 304-9.
12. Acosta MT, Gioia GA, Silva AJ. Neurofibromatosis type 1: new insights into neurocognitive issues. Curr Neurol Neurosci Rep 2006; 6: 136-43.
13. Anderson P, Green S (2002) Cochrane Collaboration Open Learning Material for Reviewers. http://www.cochrane-net.org/openlearning/ (accessed 13 June 2012).
14. Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Policy 2005; 10(Suppl. 1): 6-20.
15. Dilts CV, Carey JC, Kircher JC, et al.Children and adolescents with neurofibromatosis 1: a behavioral phenotype. J Dev Behav Pediatr 1996; 17: 229-39.
16. Hofman KJ, Harris EL, Bryan RN, Denckla MB. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994; 124: S1-8.
17. Krab LC, Aarsen FK, de Goede-Bolder A, et al.Impact of neurofibromatosis type 1 on school performance. J Child Neurol 2008; 23: 1002-10.
18. Cutting LE, Koth CW, Denckla MB. How children with neurofibromatosis type 1 differ from 'typical' learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol 2000; 17: 29-47.
19. Mazzocco M, Turner J, Denckla M, Hofman K, Scanlon D, Vellutino F. Language and reading deficits associated with neurofibromatosis type 1: evidence for a not-so-nonverbal learning disability. Dev Neuropsychol 1995; 11: 503-22.
20. North K, Joy P, Yuille D, Cocks N, Hutchins P. Cognitive function and academic performance in children with neurofibromatosis type 1. Dev Med Child Neurol 1995; 37: 427-36.
21. Cutting LE, Levine TM. Cognitive profile of children with neurofibromatosis and reading disabilities. Child Neuropsychol 2010; 16: 417-32.
22. Eldridge R, Denckla MB, Bien E, et al.Neurofibromatosis type 1 (Recklinghausen's disease). Neurologic and cognitive assessment with sibling controls. Am J Dis Child 1989; 143: 833-7.
23. Billingsley RL, Slopis JM, Swank PR, Jackson EF, Moore BD Cortical morphology associated with language function in neurofibromatosis, type I. Brain Lang 2003; 85: 125-39.
24. Moore BD 3rd, Slopis JM, Jackson EF, De Winter AE, Leeds NE. Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology 2000; 54: 914-20.
25. Moore BD, Slopis JM, Schomer D, Jackson EF, Levy BM. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology 1996; 46: 1660-8.
26. Payne JM, Hyman SL, Shores EA, North KN. Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behavior. Child Neuropsychol 2011; 17: 313-29.
27. Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN. Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol 2010; 25: 834-41.
28. Watt SE, Shores A, North KN. An examination of lexical and sublexical reading skills in children with neurofibromatosis type 1. Child Neuropsychol 2008; 14: 401-18.
29. Alivuotila L, Hakokari J, Visnapuu V, et al.Speech characteristics in neurofibromatosis type 1. Am J Med Genet A 2010; 152A: 42-51.
30. Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD 3rd. Functional magnetic resonance imaging of phonologic processing in neurofibromatosis 1. J Child Neurol 2003; 18: 731-40.
31. Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD. Functional MRI of visual-spatial processing in neurofibromatosis, type I. Neuropsychologia 2004; 42: 395-404.
32. Brewer VR, Moore BD 3rd, Hiscock M. Learning disability subtypes in children with neurofibromatosis. J Learn Disabil 1997; 30: 521-33.
33. Clements-Stephens AM, Rimrodt SL, Gaur P, Cutting LE. Visuospatial processing in children with neurofibromatosis type 1. Neuropsychologia 2008; 46: 690-7.
34. Coude FX, Mignot C, Lyonnet S, Munnich A. Academic impairment is the most frequent complication of neurofibromatosis type-1 (NF1) in children. Behav Genet 2006; 36: 660-4.
35. Descheemaeker MJ, Ghesquiere P, Symons H, Fryns JP, Legius E. Behavioural, academic and neuropsychological profile of normally gifted Neurofibromatosis type 1 children. J Intellect Disabil Res 2005; 49(Pt 1): 33-46.
36. Hyman SL, Arthur Shores E, North KN. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 2006; 48: 973-7.
37. Eliason MJ. Neurofibromatosis: implications for learning and behavior. J Dev Behav Pediatr 1986; 7: 175-9.
38. Erdoǧan-Bakar E, Cinbis M, Ozyurek H, Kiris N, Altunbasak S, Anlar B. Cognitive functions in neurofibromatosis type 1 patients and unaffected siblings. Turk J Pediatr 2009; 51: 565-71.
39. Schrimsher GW, Billingsley RL, Slopis JM, Moore BD 3rd. Visual-spatial performance deficits in children with neurofibromatosis type-1. Am J Med Genet A 2003; 120A: 326-30.
40. Ullrich NJ, Ayr L, Leaffer E, Irons MB, Rey-Casserly C. Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol 2010; 25: 1195-202.
41. Billingsley RL, Schrimsher GW, Jackson EF, Slopis JM, Moore BD 3rd. Significance of planum temporale and planum parietale morphologic features in neurofibromatosis type 1. Arch Neurol 2002; 59: 616-22.
42. Bawden H, Dooley J, Buckley D, et al.MRI and nonverbal cognitive deficits in children with neurofibromatosis 1. J Clin Exp Neuropsychol 1996; 18: 784-92.
43. De Winter AE, Moore BD 3rd, Slopis JM, Ater JL, Copeland DR. Brain tumors in children with neurofibromatosis: additional neuropsychological morbidity?Neuro Oncol 1999; 1: 275-81.
44. Feldmann R, Denecke J, Grenzebach M, Schuierer G, Weglage J. Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities. Neurology 2003; 61: 1725-8.
45. Huijbregts S, Swaab H, de Sonneville L. Cognitive and motor control in neurofibromatosis type I: influence of maturation and hyperactivity-inattention. Dev Neuropsychol 2010; 35: 737-51.
46. Johnson BA, MacWilliams BA, Carey JC, Viskochil DH, D'Astous JL, Stevenson DA. Motor proficiency in children with neurofibromatosis type 1. Pediatr Phys Ther 2010; 22: 344-8.
47. Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJ, Huijbregts SC. Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology 2009; 23: 50-60.
48. Krab LC, de Goede-Bolder A, Aarsen FK, et al.Motor learning in children with neurofibromatosis type I. Cerebellum 2011; 10: 14-21.
49. Dunn DW, Roos KL. Magnetic resonance imaging evaluation of learning difficulties and incoordination in neurofibromatosis. Neurofibromatosis 1989; 2: 1-5.
50. Kaplan AM, Chen K, Lawson MA, Wodrich DL, Bonstelle CT, Reiman EM. Positron emission tomography in children with neurofibromatosis-1. J Child Neurol 1997; 12: 499-506.
51. Spaepen A, Borghgraef M, Fryns JP. Von Recklinghausen-neurofibromatosis: a study of the psychological profile. Birth Defects Orig Artic Ser 1992; 28: 85-91.
52. Gilboa Y, Josman N, Fattal-Valevski A, Toledano-Alhadef H, Rosenblum S. The handwriting performance of children with NF1. Res Dev Disabil 2010; 31: 929-35.
53. Stevenson DA, Murray M, Viskochil DH, Carey JC, Moyer-Mileur LJ. Bone mineral density in children with neurofibromatosis type 1. J Pediatr Orthop 2008; 28: 791; author reply 791-2.
54. Souza JF, Passos RL, Guedes AC, Rezende NA, Rodrigues LO. Muscular force is reduced in neurofibromatosis type 1. J Musculoskelet Neuronal Interact 2009; 9: 15-7.
55. Gottfredson LS. Foreword to 'Intelligence and social policy'. Intelligence 1997; 24: 1-12.
56. Ferner RE, Hughes RA, Weinman J. Intellectual impairment in neurofibromatosis 1. J Neurol Sci 1996; 138: 125-33.
57. Greenwood RS, Tupler LA, Whitt JK, et al.Brain morphometry, T2-weighted hyperintensities, and IQ in children with neurofibromatosis type 1. Arch Neurol 2005; 62: 1904-8.
58. Roy A, Roulin JL, Charbonnier V, et al.Executive dysfunction in children with neurofibromatosis type 1: a study of action planning. J Int Neuropsychol Soc 2010; 16: 1056-63.
59. Varnhagen CK, Lewin S, Das JP, Bowen P, Ma K, Klimek M. Neurofibromatosis and psychological processes. J Dev Behav Pediatr 1988; 9: 257-65.
60. Legius E, Descheemaeker MJ, Spaepen A, Casaer P, Fryns JP. Neurofibromatosis type 1 in childhood: a study of the neuropsychological profile in 45 children. Genet Couns 1994; 5: 51-60.
61. Wadsby M, Lindehammar H, Eeg-Olofsson O. Neurofibromatosis in childhood: neuropsychological aspects. Neurofibromatosis 1989; 2: 251-60.
62. Fuster J. Memory in the Cerebral Cortex: An Empirical Approach to Neural Networks in the Human and Nonhuman Primate. Cambridge, MA: MIT Press, 1995.
63. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior Rating Inventory of Executive Function, Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc., 2000.
64. Shallice T. From Neuropsychology to Mental Structure. New York: Cambridge University Press, 1988.
65. Stuss DT, Benson DF. The Frontal Lobes. New York: Raven Press, 1986.
66. Rabbitt P. Methodologies and models in the study of executive function. In: Rabbitt P, editor. Methodology of Frontal and Executive Function. Hove: Psychology Press Publishers, 1997; 1-38.
67. Lavie N. Capacity limits in selective attention: behavioral evidence and implications for neural activity. In: Braun J, editor. Visual Attention and Cortical Circuits. Cambridge, MA: MIT Press, 2001; 48-69.
68. Luck S, Hillyard S. The operation of selective attention at multiple stages of processing: evidence from human and monkey electrophysiology. In: Gazzaniga M, editor. The New Cognitive Neurosciences, 2nd edn. Cambridge, MA: MIT Press, 2000; 687-700.
69. Gilboa Y, Rosenblum S, Fattal-Valevski A, Toledano-Alhadef H, Rizzo AS, Josman N. Using a Virtual Classroom environment to describe the attention deficits profile of children with Neurofibromatosis type 1. Res Dev Disabil 2011; 32: 2608-13.
70. Koth CW, Cutting LE, Denckla MB. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 2000; 6: 185-94.
71. Coude FX, Mignot C, Lyonnet S, Munnich A. Early grade repetition and inattention associated with neurofibromatosis type 1. J Atten Disord 2007; 11: 101-5.
72. Mautner VF, Kluwe L, Thakker SD, Leark RA. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002; 44: 164-70.
73. Reber AS, Reber E. The Penguin Dictionary of Psychology. New York: Penguin Books, 2001.
74. Case R. The whole child: towards an integrated view of young children's cognitive, social and emotional development. In: Pellegrini A, editor. Psychological Bases of Early Education. Chichester: John Wiley & Sons, 1988; 155-84.
75. Gaulin S, McBurney D. Evolutionary Psychology. Upper Saddle River, NJ: Prentice Hall, 2004.
76. Dodge K, Garber J. Domains of emotion regulation. In: Garber J, Dodge K, editors. The Development of Emotion Regulation and Dysregulation. New York: Cambridge University Press, 1991; 3-14.
77. DeGangi G. Pediatric Disorders of Regulation in Affect and Behavior: A Therapist's Guide to Assessment and Treatment. San Diego: Academic Press, 2000.
78. Douglas J. Behaviour Problems in Young Children: Assessment and Management. London: Tavistock/Routledge, 2002.
79. Barton B, North K. Social kills of children with neurofibromatosis type 1. Dev Med Child Neurol 2004; 46: 553-63.
80. Noll RB, Reiter-Purtill J, Moore BD, et al.Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A 2007; 143A: 2261-73.
81. Johnson NS, Saal HM, Lovell AM, Schorry EK. Social and emotional problems in children with neurofibromatosis type 1: evidence and proposed interventions. J Pediatr 1999; 134: 767-72.
82. Huijbregts SC, de Sonneville LM. Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1?Behav Genet 2011; 41: 430-6.
83. Rose-Krasnor L. The nature of social competence: a review. Soc Dev 1997; 6: 111-35.
84. Gresham FM. Social skills and learning disabilities: causal, concomitant, or correlational. School Psychol Rev 1992; 21: 348-60.
85. Rubin KH, Bukowski W, Parker JG. Peer interactions, relationships, and groups. In: Damon W, Eisenberg N, editors. Handbook of Child Psychology: Social, Emotional and Personality Development, 5th edn. New York: Wiley, 1998; 619-700.
86. Huijbregts S, Jahja R, De Sonneville L, de Breij S, Swaab-Barneveld H. Social information processing in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol 2010; 52: 620-5.
87. Cutting L, Clements A, Lightman A, Yerby-Hammack P, Denckla M. Cognitive profile of neurofibromatosis type 1: rethinking nonverbal learning disabilities. Learn Disabil Res Pract 2004; 19: 155-65.
88. Barton B, North K. The self-concept of children and adolescents with neurofibromatosis type 1. Child Care Health Dev 2007; 33: 401-8.
89. Goodman R, Yude C. IQ and its predictors in childhood hemiplegia. Dev Med Child Neurol 1996; 38: 881-90.
90. Dennis M, Francis DJ, Cirino PT, Schachar R, Barnes MA, Fletcher JM. Why IQ is not a covariate in cognitive studies of neurodevelopmental disorders. J Int Neuropsychol Soc 2009; 15: 331-43.
91. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev 2007; 2: MR000010.
92. Krab LC, de Goede-Bolder A, Aarsen FK, et al.Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008; 300: 287-94.
93. Lorenzo J, Barton B, Acosta MT, North K. Mental, motor, and language development of toddlers with neurofibromatosis type 1. J Pediatr 2011; 158: 660-5.
94. Sangster J, Shores EA, Watt S, North KN. The cognitive profile of preschool-aged children with neurofibromatosis type 1. Child Neuropsychol 2011; 17: 1-16.
95. Goh WH, Khong PL, Leung CS, Wong VC. T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function. J Child Neurol 2004; 19: 853-8.
96. Stine SB, Adams WV. Learning problems in neurofibromatosis patients. Clin Orthop Relat Res 1989; 245: 43-8.